Pre-MEASURE: Multicenter evaluation of the prognostic significance of measurable residual disease testing prior to allogeneic transplantation for adult patients with AML in first remission.
Chris S. Hourigan(National Institutes of Health), Kristin Page(Medical College of Wisconsin), Antonio Jiménez(University of Miami), Zoë C. Wong(National Institutes of Health), Chris J. M. Yoon(National Marrow Donor Program), Devdeep Mukherjee(National Institutes of Health), Alan Howard(National Marrow Donor Program), Firas El Chaer(The University of Texas MD Anderson Cancer Center), Georgia Andrew(National Institutes of Health), Gege Gui(Johns Hopkins University), Laura W. Dillon(Institute of Cancer Research), Wael Saber(Medical College of Wisconsin), Stephen R. Spellman(National Marrow Donor Program), Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Daniel J. Weisdorf(University of Minnesota), Mark R. Litzow(Mayo Clinic in Arizona), Jeffery J. Auletta(Nationwide Children's Hospital), Niveditha Ravindra(National Institutes of Health), Marcos J.G. De Lima(The Ohio State University), Steven M. Devine(National Marrow Donor Program)
Cited by 11
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907